US Patent 11,311,620: Scope, Claims, Expiration, Litigation Risk and Bladder-Cancer Patent Landscape

US Patent 11,311,620 covers a neoadjuvant bladder-cancer treatment method using intravesical hexyl 5-aminolevulinate, also called hexyl 5-ALA or HAL, followed by illumination of the bladder before cystectomy. Its broadest claim is limited by four central elements: a qualifying bladder-cancer patient, planned cystectomy, intravesical HAL administration with light exposure, and a maximum four-week interval before surgery.

The patent is materially broader than the currently established diagnostic use of HAL, but its commercial scope depends on whether the claimed neoadjuvant therapeutic protocol is clinically adopted, whether the relevant product labeling supports the method, and whether the patent survives enablement, written-description, obviousness, and claim-construction challenges.

What does US Patent 11,311,620 claim?

US Patent 11,311,620 claims a method of neoadjuvant therapy for:

Muscle-invasive bladder cancer, or MIBC;
Non-muscle-invasive bladder cancer, or NMIBC, when the disease has a high risk of progression;
Patients scheduled to undergo cystectomy.

The claimed treatment requires:

Instilling a composition containing HAL or a pharmaceutically acceptable HAL salt into the bladder;
Exposing the inside of the bladder to light;
Performing the cystectomy zero to four weeks after the neoadjuvant therapy.

Claim 1 is the controlling independent claim. Claims 2 through 23 narrow the method by specifying the cancer type, HAL salt, concentration, vehicle, dwell time, light source, sequencing, combination therapy, and shorter surgery interval.

Core claim elements

Element	Requirement in claim 1	Commercial significance
Disease	MIBC or high-risk NMIBC	Excludes ordinary low-risk NMIBC
Patient status	Patient scheduled for cystectomy	Links treatment to a surgical pathway
Drug	HAL or pharmaceutically acceptable salt	Covers free form and salts
Route	Intravesical instillation	Excludes systemic administration
Light	Exposure of the inside of the bladder	Requires a photoactivation or illumination step
Timing	Cystectomy zero to four weeks after treatment	Creates the principal temporal limitation
Therapeutic setting	Neoadjuvant therapy	Positions the use before definitive surgery

The claim does not expressly require a particular tumor response, photodynamic mechanism, light dose, energy density, number of treatment cycles, or specific cystoscope. Those omissions expand the literal claim scope but may create validity and enablement issues if the specification does not support the full breadth.

What formulations are protected by US 11,311,620?

The patent protects both broad formulation categories and a specific 0.2% aqueous phosphate-buffer formulation.

Claim 6 covers HAL at 0.1% to 5% by weight, or the equivalent concentration of a pharmaceutically acceptable salt. Claim 7 extends to semi-solid and liquid formulations. Claims 8 through 10 cover liquid compositions using water or an aqueous buffer, including phosphate buffer.

Claim 11 is narrower and more commercially concrete. It covers liquid hexyl 5-ALA ester hydrochloride at 0.2% in an aqueous phosphate buffer containing:

Disodium phosphate dihydrate;
Potassium dihydrogen phosphate;
Sodium chloride;
Hydrochloric acid;
Sodium hydroxide;
Water.

Formulation claim hierarchy

Claim	Formulation limitation
1	HAL or pharmaceutically acceptable salt
4	Pharmaceutically acceptable HAL salt
5	HAL hydrochloride
6	0.1% to 5% HAL by weight
7	Semi-solid or liquid composition
8	Liquid carrier
9	Water or aqueous buffer
10	Phosphate buffer
11	0.2% HAL hydrochloride in specified phosphate-buffer system

A competing product may avoid claim 11 by changing concentration, buffer composition, excipients, or salt form. That does not necessarily avoid claim 1, which does not require the claim 11 formulation.

How do the light-exposure claims affect infringement risk?

Claims 14 through 17 specify white, blue, and red light. Claim 15 covers red light. Claims 16 and 17 cover white and blue light, including white light followed by blue light.

The light limitations produce different risk profiles:

Blue-light cystoscopy is closely associated with HAL fluorescence-based bladder visualization.
Red-light activation is more consistent with therapeutic photodynamic-treatment concepts.
White-light exposure alone may raise a technical and construction issue because ordinary cystoscopic visualization may not provide a therapeutic photodynamic effect.
Claim 17 is limited to white light followed by blue light and may capture a diagnostic illumination sequence used in a HAL-based procedure.

The patent claims exposure of the inside of the bladder, not a specific irradiance or wavelength bandwidth. A product or procedure using a different light source could still fall within claim 1 unless the relevant jurisdiction construes “light” more narrowly based on the specification and prosecution history.

What are the timing requirements before cystectomy?

The principal timing limitation is zero to four weeks between the HAL/light treatment and cystectomy. Claims 21, 22, and 23 narrow that period to:

Zero to three weeks;
Zero to two weeks;
Zero to one week.

“Zero” potentially covers treatment performed on the same day as cystectomy, depending on how the claim is construed. The timing limitation is commercially important because it ties the claimed use to the preoperative treatment window rather than to long-term bladder surveillance or repeated maintenance therapy.

Timing claim matrix

Claim	Maximum interval before cystectomy
1	Four weeks
21	Three weeks
22	Two weeks
23	One week

A procedure performed more than four weeks before cystectomy would fall outside the express timing limitation of claim 1, unless another theory of infringement applied. A procedure performed within one week could implicate claims 1, 21, 22, and 23 if all other limitations are met.

What administration and illumination steps are protected?

Claim 12 requires catheter instillation and a bladder dwell time of approximately 20 minutes to three hours. Claim 13 requires at least one hour between instillation and the start of light exposure.

These limitations create a protocol-level claim rather than merely a drug-use claim. A treatment that uses catheter administration but removes the composition before 20 minutes may avoid claim 12 while remaining potentially within claim 1. Conversely, a protocol with less than one hour between instillation and light exposure may avoid claim 13 but not necessarily the independent claim.

Procedure limitations

Claim	Protocol limitation
12	Catheter instillation; dwell time about 20 minutes to about three hours
13	At least one hour from instillation to light exposure
14	White, blue, and/or red light
15	Red light
16	White and blue light
17	White light followed by blue light

The patent therefore creates several fallback positions. A challenger may avoid a narrower dependent claim while still facing claim 1.

Does the patent cover combination therapy with immunotherapy?

Claims 18 through 20 address combination treatment.

Claim 18 permits the HAL/light therapy to occur before, simultaneously with, or after other neoadjuvant therapies. Claims 19 and 20 specify anti-PD-L1 and anti-PD-1 antibodies. The claims therefore reach protocols combining intravesical HAL/light treatment with checkpoint inhibitors, provided the other claim elements are satisfied.

The claims do not identify a specific antibody such as pembrolizumab, atezolizumab, nivolumab, durvalumab, or avelumab. A product-specific infringement analysis would depend on whether the accused regimen includes the claimed antibody and whether the antibody is present in the same composition or merely used as part of the overall neoadjuvant regimen.

Claim 19 states that the composition further comprises anti-PD-L1 and/or anti-PD-1 antibodies. That language may raise a practical formulation issue because intravesical co-formulation of HAL hydrochloride with a therapeutic antibody is materially different from sequential administration of separate products. Claim 18 is broader for combination regimens because it does not require the antibody to be in the HAL composition.

What is the patent’s likely expiration date?

The patent issued on April 26, 2022. Public patent records identify a priority date in the 2019 period and a corresponding international filing route. On a standard 20-year patent-term calculation, the expected expiration is approximately January 2039 or January 2040, depending on the earliest effective nonprovisional or PCT filing date used for the US term calculation.

The exact enforceable expiration requires review of:

The front page and continuity data;
The earliest effective US or PCT filing date;
Patent-term adjustment, or PTA;
Any terminal disclaimer;
Any patent-term extension, or PTE.

A PTE is unlikely to be available merely because HAL is used in a new surgical protocol unless the relevant regulatory approval and statutory requirements are satisfied. The more immediate term issue is PTA, which may extend the ordinary expiration date beyond the basic 20-year calculation.

How strong is the patent estate for HAL neoadjuvant therapy?

The estate appears strongest against a protocol that reproduces all of the following:

MIBC or high-risk NMIBC;
Planned cystectomy;
Intravesical HAL hydrochloride;
0.2% aqueous phosphate-buffer formulation;
Catheter dwell time of 20 minutes to three hours;
At least one hour before illumination;
Blue or red light;
Cystectomy within one to four weeks.

The estate is weaker against:

HAL treatment without planned cystectomy;
Treatment performed more than four weeks before surgery;
Non-HAL photosensitizers;
Systemic administration;
A light-based procedure that does not expose the bladder interior;
A treatment in patients not scheduled for cystectomy;
Low-risk NMIBC outside the claimed disease population.

Strength by claim category

Claim category	Relative strength	Principal vulnerability
Core neoadjuvant method	High commercial relevance	Obviousness and support for broad “light” language
HAL salt and concentration	Moderate to high	Design-around through concentration or formulation
Specific phosphate formulation	High product specificity	Easy formulation substitution
Catheter dwell time	Moderate	Protocol modification
One-hour light delay	Moderate	Timing modification
Red-light treatment	Potentially significant	Prior-art photodynamic therapy
White/blue light sequence	Stronger overlap with diagnostic practice	Written description and claim construction
Checkpoint-inhibitor combination	Potentially broad	Co-formulation and enablement issues
One-week surgery window	Narrow but actionable	Scheduling outside the window

How does US 11,311,620 compare with Cysview and existing HAL rights?

HAL is commercially associated with Cysview in the United States and Hexvix in certain non-US markets. FDA approved Cysview for use with blue-light cystoscopy to detect bladder cancer, not as a neoadjuvant treatment intended to treat tumors before cystectomy.[2]

That distinction is central. Existing HAL diagnostic rights and labeling may cover:

Intravesical administration;
Fluorescence-based visualization;
Blue-light cystoscopy;
Detection of bladder lesions.

US 11,311,620 adds a therapeutic and surgical-purpose limitation:

The patient is scheduled for cystectomy;
The therapy is neoadjuvant;
Cystectomy follows within four weeks;
The use is directed to MIBC or high-risk NMIBC.

The patent therefore does not simply claim ordinary Cysview diagnostic use. It targets a new treatment context built around preoperative HAL exposure and illumination.

Comparison with established bladder-cancer therapies

Therapy	Primary use	Relationship to US 11,311,620
Cysview/HAL blue-light cystoscopy	Diagnostic visualization	Potentially relevant to drug and device components, but not necessarily the claimed neoadjuvant purpose
Intravesical BCG	High-risk NMIBC treatment	Competing or combination neoadjuvant therapy
Intravesical gemcitabine	NMIBC treatment and perioperative use	Potential alternative or combination therapy
Mitomycin C	Intravesical chemotherapy	Alternative intravesical treatment
Pembrolizumab	Systemic checkpoint inhibition	Potential combination therapy under claims 18-20
Enfortumab vedotin plus pembrolizumab	Systemic treatment for advanced urothelial carcinoma	Competing systemic regimen; potentially relevant to combination protocols
Radical cystectomy	Definitive surgery	Required downstream event in the asserted method
Other photodynamic therapies	Drug-light tumor treatment	Potential prior art and design-around technologies

What is the Orange Book status of US 11,311,620?

The patent is not automatically an Orange Book patent merely because it concerns an FDA-approved active ingredient. Orange Book listing depends on whether the patent claims the approved drug substance, drug product, or an approved method of use, and whether the NDA holder submits the patent in accordance with FDA requirements.[3]

Cysview’s FDA-approved use is diagnostic blue-light cystoscopy. The claims of US 11,311,620 are directed to neoadjuvant therapy before cystectomy. If that indication is not included in the approved labeling, the patent may not qualify for listing as an approved method-of-use patent for the existing Cysview indication.

That distinction affects generic litigation. A future abbreviated new drug application, or ANDA, directed to Cysview’s diagnostic indication would not necessarily trigger a Paragraph IV dispute over a patent that claims only the unapproved neoadjuvant use. Conversely, a sponsor seeking approval for the patented neoadjuvant indication could face a more direct patent certification issue if the patent is listed and otherwise eligible.

Which companies are likely to challenge or design around the patent?

The most direct commercial parties are:

Photocure and its US commercial partners, as holders or commercializers of HAL-based Cysview rights;
Generic or follow-on developers of hexaminolevulinate products;
Bladder-cancer drug developers pursuing perioperative immunotherapy;
Medical-device companies supplying blue-, white-, or red-light cystoscopy systems;
Hospitals or surgical networks implementing the protocol at scale.

A conventional generic Cysview entrant would have a stronger noninfringement position if its proposed labeling is limited to FDA-approved diagnostic use and omits the neoadjuvant cystectomy protocol. An ANDA sponsor could still face inducement allegations if promotional materials, physician instructions, or labeling encourage the patented use.

A device-only supplier generally would not directly practice the method unless it also participates in the treatment protocol. Its exposure may arise through contributory or inducement theories, which depend on the device’s specific use, knowledge, and substantial non-infringing uses.

What Paragraph IV and litigation risks exist?

The supplied claim set does not establish that a Paragraph IV certification, federal district-court complaint, settlement, or license exists. Patent-risk analysis should separate four scenarios.

Generic diagnostic launch

A generic HAL product limited to blue-light diagnostic cystoscopy has a stronger design-around position because it would omit the neoadjuvant purpose and cystectomy timing. Risk increases if the labeling refers to preoperative treatment or claims therapeutic benefit.

Neoadjuvant HAL launch

A product or protocol expressly directed to MIBC or high-risk NMIBC patients scheduled for cystectomy would likely practice claim 1 if it includes intravesical HAL and bladder illumination within the four-week window.

Combination immunotherapy launch

A regimen combining HAL/light treatment with an anti-PD-1 or anti-PD-L1 antibody could implicate claims 18 through 20. The strongest risk would arise where the HAL treatment is administered as part of a defined preoperative regimen and the patient proceeds to cystectomy within the claimed period.

Hospital protocol adoption

Hospitals can create infringement exposure by adopting a standardized pathway that mirrors the claim limitations, even when the HAL product itself is lawfully marketed for diagnostic use. Protocol documents, order sets, investigator brochures, and treatment scheduling records would be important evidence in any inducement analysis.

What manufacturing and intellectual-property barriers matter?

The formulation claims create limited but real manufacturing barriers. A commercial developer must control:

HAL salt selection;
Concentration and assay;
Buffer pH;
Stability in aqueous solution;
Sterility and container compatibility;
Light sensitivity;
Intravesical dwell-time performance;
Compatibility with the cystoscopic illumination system.

Claim 11 is easier to design around than claim 1 because the detailed excipient list and 0.2% concentration can be changed. The broader method claim remains the principal barrier because it does not require that exact formulation.

The light system also creates a separate freedom-to-operate issue. A developer may need rights to the cystoscope, light source, imaging software, optical filters, and disposable catheter components. Those rights are distinct from the HAL drug patent.

How does US 11,311,620 compare with competing patent strategies?

The patent uses a use-and-protocol strategy rather than a composition-only strategy. Its protection is concentrated in the clinical sequence:

Select a high-risk surgical patient;
Instill HAL;
Illuminate the bladder;
Proceed to cystectomy within a short period.

A competing company may instead pursue:

A different photosensitizer;
A different light wavelength;
Systemic rather than intravesical administration;
A post-cystectomy adjuvant use;
Treatment without a planned cystectomy;
A formulation outside the claimed concentration;
A regimen in which immunotherapy is administered separately rather than in the same composition.

These alternatives may avoid some dependent claims, but they do not automatically avoid claim 1 if HAL, intravesical administration, bladder illumination, and the four-week surgical interval remain present.

Key Takeaways

US 11,311,620 is a method patent covering HAL-based neoadjuvant treatment before cystectomy.
Claim 1 requires MIBC or high-risk NMIBC, planned cystectomy, intravesical HAL, bladder illumination, and surgery within zero to four weeks.
Claims 6 and 11 create formulation protection, including 0.1% to 5% HAL and a specific 0.2% HAL hydrochloride phosphate-buffer formulation.
Claims 12 through 17 protect administration timing, dwell time, light timing, and selected light sequences.
Claims 18 through 20 extend the estate to combination use with other neoadjuvant therapies and checkpoint inhibitors.
The expected patent term runs approximately to 2039 or 2040, subject to the official patent-term calculation, PTA, and any terminal disclaimer.
Cysview’s established FDA use is diagnostic blue-light cystoscopy. The patent targets a separate neoadjuvant therapeutic use before cystectomy.
A generic diagnostic launch has a stronger design-around position than a product labeled or promoted for HAL-based neoadjuvant treatment.
The principal validity risks are obviousness, written description, enablement, and construction of the broad “light” and neoadjuvant-treatment limitations.
The principal commercial risk is a hospital or drug-device protocol that reproduces the full claim 1 sequence.

FAQs About US Patent 11,311,620

Does US 11,311,620 cover Cysview for ordinary blue-light cystoscopy?

Not necessarily. The patent claims a neoadjuvant use in patients scheduled for cystectomy. Ordinary diagnostic blue-light cystoscopy without the claimed surgical context does not necessarily satisfy claim 1.

Can a HAL product avoid infringement by changing the concentration?

Changing concentration may avoid claim 6 or claim 11. It may not avoid claim 1, which does not specify a concentration, if the product is used in the claimed neoadjuvant protocol.

Does the patent cover MIBC treatment without cystectomy?

The claims require a patient scheduled for cystectomy and a defined interval before cystectomy. A HAL/light treatment without planned cystectomy would have a stronger noninfringement position.

Is red-light photodynamic therapy covered?

Red-light treatment is expressly covered by claim 15 when the other limitations of the applicable claim are satisfied. Red-light systems may also face separate patent rights relating to the device, photosensitizer, dose, and irradiation parameters.

Can a hospital use HAL before cystectomy without a license?

A hospital protocol may create infringement risk if it administers HAL intravesically, illuminates the bladder, treats the claimed patient population, and schedules cystectomy within the claimed four-week period. The risk depends on the exact protocol and applicable claim construction.

References

United States Patent and Trademark Office. (2022). U.S. Patent No. 11,311,620, Neoadjuvant therapy for bladder cancer.
U.S. Food and Drug Administration. (2010). Cysview: Prescribing information and approval materials.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Bladder cancer.
United States Code, 35 U.S.C. §§ 154, 271, and 355.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010		RX	Yes	Yes	11,311,620	⤷ Start Trial				DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016372573	⤷ Start Trial
Brazil	112018012009	⤷ Start Trial
Canada	3008551	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,311,620

Which drugs does patent 11,311,620 protect, and when does it expire?

Summary for Patent: 11,311,620